Over the past two decades, Octapharma USA, Inc. has achieved many milestones, securing multiple FDA approvals and successfully passing inspections of all Octapharma production sites. Today, we offer a portfolio of ten FDA-registered products in the USA. Read the full story here: https://bit.ly/4bmJ9Qs
Octapharma
Pharmaceutical Manufacturing
Lachen, Switzerland 49,123 followers
Our passion drives us to provide new health solutions advancing human life
About us
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml
- Website
-
http://www.octapharma.com
External link for Octapharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lachen, Switzerland
- Type
- Privately Held
- Founded
- 1983
- Specialties
- Plasma Fractionation, Haematology, Immunotherapy, and Critical Care
Locations
Employees at Octapharma
Updates
-
The first few months of Deni's life were just like those of most children, filled with sleeping, nappy changes and bottle feeds. It wasn't until he was 18 months old that he had his first muscle bleed and bruising on his legs. Luckily for Deni, his haemophilia was diagnosed early, but many other haemophilia patients in Indonesia lack proper diagnosis and adequate care. Read his story here: https://bit.ly/441xrb2
Access for everyone: Learning to live with haemophilia
octapharma.com
-
The next patient case from our Clinical Practice online series goes live on One Source on Wednesday, May 22 at 17:30 CET. Join us and Dr. Carmen Escuriola Ettingshausen for an interactive session in which we discuss immune tolerance induction with FVIII concentrate concomitant with emicizumab, and take your questions. Sign up for the session here: https://bit.ly/4dqCtCd The event is for healthcare professionals only.
-
-
Octapharma USA, Inc. announces that our VWF concentrate has been granted orphan drug exclusivity by the FDA, making it the first such treatment indicated for prophylaxis across all types of von Willebrand disease (#VWD) in both adults and children aged 6 and above. This groundbreaking development marks a significant step forward in the care of patients with VWD, the most prevalent bleeding disorder in the USA. Read the press release here: https://bit.ly/3QoyzQw
-
-
Trainee programs are integral to Octapharma’s learning and development portfolio and talent pipeline. By investing in young professionals, we ensure a strong foundation for our future. This spring, we celebrate the successful completion of the 2022 trainee cohort's program. Read the inspiring trainee journeys of Maja Warlin, Maiko Blaukopf, and Fabian Grasser here: https://bit.ly/3WksPec
Advancing talent at Octapharma
octapharma.com
-
Maria Isabel, a chef from Mexico, has lived with common variable immunodeficiency (CVID), a primary immunodeficiency disease (PID), for her entire life. To help break the stigma of PIDs in Mexico and around the world, she wants other patients to know that it is possible to live a full life with proper treatment. Watch her full story here: https://bit.ly/3Ik5qBq #WorldPIweek
-
Primary immunodeficiency diseases (PIDs) comprise a group of over 400 rare, chronic disorders in which part of the immune system is either missing or functions improperly. Unfortunately, diagnosis is often delayed, and patients may be misdiagnosed due to low awareness. Maria Isabel lives in Mexico and has been diagnosed with common variable immunodeficiency (CVID), a primary immunodeficiency disease. Read her story to learn how she has overcome this life-changing condition: https://bit.ly/3Ik5qBq #WorldPIWeek
-
-
When Deni was growing up in Jakarta during the 1990s, treatment for haemophilia was not widely available in Indonesia. While progress has been made since then, significant gaps in addressing bleeding disorders remain. World Haemophilia Day is celebrated on April 17 each year to increase awareness of bleeding disorders. By fostering understanding and education, we pave the way for improved diagnosis and treatment worldwide. Watch Deni's full story here: https://bit.ly/441xrb2 #WHD2024 #WorldHaemophiliaDay
-
Join Víctor Jiménez Yuste, Robert F. Sidonio Jr., Craig Kessler, Viola Vogel and Robert Klamroth at #WFH2024 in Madrid, where the final results of the largest clinical study in prophylaxis for VWD will be presented alongside new scientific data investigating the importance of platelets in haemostasis and understanding joint and bone health in haemophilia A patients. Come join us at our Under the Spotlight symposium on Monday, April 22 at 18:30: https://bit.ly/4aYSldl The symposium is for HCPs only.
-
The next patient case from our Clinical Practice online series goes live on One Source on Tuesday, April 16 at 17:00 CET. Join us and Dr. Ana Boban from University Hospital Centre Zagreb, Croatia, for an interactive session in which we will discuss the use of prophylaxis to reduce nosebleeds in a von Willebrand disease patient, and take your questions. Sign up for the session here: https://bit.ly/43SuV6R The event is for healthcare professionals only.
Clinical Practice: Use of prophylaxis to reduce nosebleeds in a von Willebrand disease patient
events.docintel.app